Endpoints and clinical trial design for nonalcoholic steatohepatitis.

  title={Endpoints and clinical trial design for nonalcoholic steatohepatitis.},
  author={Arun J Sanyal and Elizabeth M. Brunt and David E Kleiner and Kris V. Kowdley and Naga Chalasani and Joel E. Lavine and Vlad Ratziu and Arthur McCullough},
  volume={54 1},
UNLABELLED Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease. At present, a liver biopsy is the only generally acceptable method for the diagnosis of NASH and assessment of its progression toward cirrhosis. Although several treatments have shown evidence of… CONTINUE READING
Highly Influential
This paper has highly influenced 21 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS


Publications citing this paper.
Showing 1-10 of 185 extracted citations


Publications referenced by this paper.
Showing 1-10 of 60 references

Similar Papers

Loading similar papers…